Bladder cancer is a common malignancy. Numerous studies have demonstrated that increased expression of cyclooxygenase enzyme 2 (COX-2), which catalyzes the synthesis of prostaglandins (PGs), is associated with the development and progression of certain type of cancers, including bladder cancer. However, the exact role of COX-2/PGs play in bladder carcinogenesis remains unknown. We have recently developed a transgenic mouse model which overexpresses COX-2 under the control of a bovine keratin 5 (BK5) promoter. The BK5.COX2 mice develop high incidence of bladder transitional cell hyperplasia (TCH) and a relative lower incidence of bladder papilloma. We then conducted a micorarray gene analysis to determine the effects of COX-2 overexpression on the regulation of gene expression profile in bladder carcinogenesis. Analysis of gene array data by t-test (p<0.05) revealed 70 of the upregulated genes and 60 of the downregulated genes had expression changed by 2-fold or more in transgenic compared to wild-type bladders. Gene set analysis using Expression Analysis Systematic Explorer software revealed that genes associated with Immune/Stress Response and Cell Cycle/Proliferation biologic processes were significantly overrepresented in the top 100 upregulated genes. Relevant downregulated genes included three TGF beta related genes (Tgfb2, Tgfb3, Tgfbi), and the anti-angiogenic gene thrombospondin 2 (Thbs2). We further demonstrated that the growth factor, epiregulin, is the most highly induced gene among the genes validated by real-time PCR. The results of gene expression analysis indicate that the initial response of the mouse bladder to elevated COX-2 expression includes mounting an inflammatory response and inducing cell proliferation. Future studies will focus on determining the role of the immune response in promoting or inhibiting the hyperplastic response of the bladder transitional epithelium. The role of epiregulin and the downstream signaling molecules in bladder carcinogenesis will also be determined. This study was supported by grants CA091865 and CA100140 from the National Cancer Institute.
INTRODUCTION METHODS

BK5.COX2 MODEL
To determine the effect of COX-2 overexpression on the gene expression profile in bladder epithelium.
To explore potential mechanisms by which COX-2 can influence urinary bladder carcinogenesis.
Real-time PCR. Total RNA from age matched wild-type and BK5.COX2 mice was isolated from tissue using TRIzol reagent and further purified using RNeasy columns. RNA from three pooled wild-type mouse bladders was used as a calibration sample. Total RNA were subsequently analyzed with the Agilent Bioanalyzer 2100 system at the OSU CCC real-time PCR shared facility. Total RNA (1µg) was reverse transcribed with iScript cDNA synthesis kit . Real-time PCR was performed on a 1:10 dilution of the cDNA using Taqman gene expression primers and ABI mastermix according to the manufacturer's instructions on an iCycler IQ Real-Time PCR detection system (Bio-Rad). GAPDH was used as the reference gene for all samples.
Affymetrix microarray and EASE Analysis. Bladder tissues were excised from 10 wk old wild-type and BK5. COX-2 transgenic mice (5 mice/group). Total RNA were extracted by TRIzol reagent and then purified by RNeasy kit. The Affymetrix microchip analysis was performed by the Microarray Core Facility at the Columbus Children's Hospital Medical Center. Ten Mouse 430 GeneChips (Affymetrix Inc., Santa Clara, CA) were used; one chip for each sample. Affymetrix MicroArray Suite was used to scan and quantitate the genechips. Intensity data were collected from each chip and hybridization data were sequentially subjected to normalization, transformation, filtering, and functional classification. Differentially expressed genes in BK5.COX2 mice versus wild-type mice were identified by log2-differences and by t-test. The results were further analyzed using Expression Analysis Systematic Explorer (EASE; NIH) with the Benjamini false discovery rate correction for multiple testing.
Tissue Preparation and Histological Analysis. Urinary bladders were excised and fixed in 10% Formalin. The fixed bladders were then bisected longitudinally through the urethral opening and positioned with the cut faces oriented in the same direction for paraffin embedding. Four-micron sections were stained with hematoxylin and eosin (H&E) by standard protocols. Immunohistochemical staining was carried out using modified ABC techniques. Primary antibody dilution for COX-2 was 1:2000 overnight at 4ºC. Species appropriate biotinylated secondary antibodies were used at 1:200 for two hours at RT followed by ABC-HRP or SA-HRP treatment for 30 minutes at RT. Slides were developed with DAB for approximately five minutes. Mouse Ki-67 staining was performed by the histopathology core at OSU. Determine the presence and level of all the prostaglandins and their respective receptors. Determine the role of epiregulin and the downstream signaling molecules in bladder carcinogenesis. Examine the interaction between COX-2 and TGF-beta signaling pathways in bladder carcinogenesis.
Immunoblot Analysis.
Explore the role of the immune response in regulating the hyperplastic response of the bladder transitional epithelium.
CONCLUSIONS
Bladder cancer represents an important heath concern. The identification of new molecular targets for bladder cancer prevention and therapy is a potential means to reduce the development and progression of this disease. Numerous studies have demonstrated that COX-2 is overexpressed in TCC of human urinary bladder [1] [2] [3] [4] . The degree of COX-2 expression is significantly correlated with the tumor grade and depth of invasion (T stage) of TCC [5] [6] [7] . Increased COX-2 expression has also been reported in rat and canine models of bladder cancer [8, 9] . A case-control study involving 1514 incident bladder cancer cases and an equal number of controls indicated that NSAID (COX inhibitors) users have an almost 20% decreased risk for urinary bladder cancer [10] . A number of studies have demonstrated that NSAIDs are able to inhibit the growth of bladder cancer cells in vitro [11] [12] [13] [14] . In addition, COX inhibitors also induced remission of chemically induced bladder tumors in rodents [15] [16] , naturally occurring invasive TCC in dogs [17] [18] , and bladder carcinoma in an orthotopic mouse model [19] . We have recently demonstrated that forced expression of COX-2, under the control of a keratin 5 (K5) promoter, is sufficient to cause urinary bladder transitional cell hyperplasia (TCH), which progresses to TCC in a small percentage of transgenic mice [20] . The level of prostaglandin E 2 (PGE 2 ), the major product of COX-2, was significantly increased in the bladder of BK5.COX2 mice. PGE 2 has also been reported to be elevated in patients with bladder cancer [4, 21] .
The above studies suggest that there is a strong association between COX-2, prostaglandin synthesis and the development and progression of urinary bladder cancer. However, the exact role and mechanisms of COX-2 overexpression during bladder carcinogenesis have not been well defined. To determine the molecular events elicited by COX-2 overexpression during the early stage of bladder carcinogenesis (before the onset of substantial TCH), we conducted DNA microarray expression analysis on urinary bladders from 10 wk old wild-type and BK5.COX2 transgenic mice. Our study is innovative in that we were able to study gene expression changes that were due solely to the overexpression of COX-2 in the bladder tissue of a novel transgenic mouse model. This model may serve as a potentially useful model to study the etiology and prevention of human urinary bladder cancer. 
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